Seeking Alpha

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

Dialogue open with FDA in preparation for End of Phase 2 Meeting request New canine elite responder biomarkers added to human biomarker strategy NEW YORK--(BUSINESS WIRE)-- OS Therapies (OSTX) (“OS ...

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

OS Animal Health (OSAH), a wholly owned OS Therapies (OSTX) subsidiary, targets an IPO on NYSE American or Nasdaq ...
Nasdaq

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology ...
Seeking Alpha

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of ...

NEW YORK--(BUSINESS WIRE)-- OS Therapies (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has ...
Morningstar

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full ...

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer ...
BioWorld

CXCL10-driven NK tumor infiltration plus IL-15 agonist to treat osteosarcoma

Osteosarcoma, the most common bone cancer in children and young adults, has poor outcomes after relapse with only ~18% 5-year survival, underscoring the urgent need for new therapies. Researchers from ...